Company Description

OKYO Pharma Limited, a clinical-stage biopharmaceutical company, develops therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom.

Its lead clinical product candidate is urcosimod, which is in Phase II clinical trials for the treatment of dry eye disease; in Phase II clinical trial to treat neuropathic corneal pain; and is in preclinical trial to treat allergic conjunctivitis and uveitis.

The company is also developing OK-201 for the treatment acute and chronic ocular pain. OKYO Pharma Limited was incorporated in 2007 and is headquartered in London, the United Kingdom.

OKYO Pharma Limited

Country	United Kingdom
Founded	2007
IPO Date	May 17, 2022
Industry	Biotechnology
Sector	Healthcare
Employees	4
CEO	Robert Dempsey

Contact Details

Address: 14/15 Conduit St, Floor 4 London, W1S 2XJ United Kingdom
Phone	44 20 7495 2379
Website	okyopharma.com

Stock Details

Ticker Symbol	OKYO
Exchange	NASDAQ
Fiscal Year	April - March
Reporting Currency	USD
IPO Price	$4.00
CIK Code	1849296
CUSIP Number	679345108
ISIN Number	GG00BMFG5F62
SIC Code	2836

Key Executives

Name	Position
Robert J. Dempsey M.B.A.	Chief Executive Officer and Executive Director
Dr. Gary S. Jacob Ph.D.	Chief Development Officer and Director
Michael Paul Beck	Founder
Keeren Shah	Chief Financial Officer
Dr. Rajkumar Patil Ph.D.	Chief Scientific Officer
Dr. Flavio Mantelli M.D., Ph.D.	Chief Medical Officer

Latest SEC Filings

Date	Type	Title
May 19, 2026	6-K	Report of foreign issuer
May 15, 2026	SCHEDULE 13G/A	Filing
May 15, 2026	SCHEDULE 13G	Filing
May 15, 2026	SCHEDULE 13G	Filing
Apr 29, 2026	6-K	Report of foreign issuer
Apr 7, 2026	6-K	Report of foreign issuer
Mar 19, 2026	6-K	Report of foreign issuer
Mar 19, 2026	6-K	Report of foreign issuer
Mar 19, 2026	6-K	Report of foreign issuer
Mar 18, 2026	6-K	Report of foreign issuer

View All SEC Filings